Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Healthcare (ACHC) is a Top-Ranked Momentum Stock: Should You Buy?
11:15am, Monday, 07'th Mar 2022
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
11:20am, Friday, 04'th Mar 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Expert Ratings For ACADIA Pharmaceuticals
09:02pm, Thursday, 03'rd Mar 2022 Benzinga
Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with underst
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
02:43pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
10:44am, Tuesday, 01'st Mar 2022
Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript
03:00am, Tuesday, 01'st Mar 2022 Seeking Alpha
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
10:35pm, Monday, 28'th Feb 2022 Zacks Investment Research
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript
10:00pm, Monday, 28'th Feb 2022
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript
Acadia Pharma down 6% after hours after earnings misses
09:52pm, Monday, 28'th Feb 2022 Seeking Alpha
Shares of Acadia Pharma (ACAD) are down ~6% in post-market trading after its Q4 2021 results missed on the top and bottom lines.Net loss narrowed in the quarter 36% to ~$43.1M
ACADIA Pharma GAAP EPS of -$0.27 misses by $0.04, revenue of $130.8M misses by $4.64M
09:10pm, Monday, 28'th Feb 2022 Seeking Alpha
ACADIA Pharma press release (ACAD): Q4 GAAP EPS of -$0.27 misses by $0.04.Revenue of $130.8M (+8.1% Y/Y) misses by $4.64M.2022 Financial Guidance: NUPLAZID net sales guidance…
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
09:05pm, Monday, 28'th Feb 2022 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021. “Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10 percent year-over-year, driven by growth in both NUPLAZID prescriptions and market share,” said Steve Davis, Chief Executive Officer. “We recently resubmitted our sNDA for pimavanserin for Alzheimer’s disease psychosis to the FDA. In
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
07:08pm, Monday, 28'th Feb 2022
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharma Q4 2021 Earnings Preview (NASDAQ:ACAD)
10:35pm, Friday, 25'th Feb 2022 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.24 and the consensus Revenue…
Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right
01:35am, Tuesday, 22'nd Feb 2022
Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right
Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know
08:00pm, Monday, 21'st Feb 2022 Zacks Investment Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
